 |
市场调查报告书
商品编码
1349857
缺血再灌流伤害治疗药市场:各治疗法，伤害，各终端用户，各地区- 规模，占有率，展望，机会分析，2023年～2030年Ischemia Reperfusion Injury Therapeutics Market, By Treatment, By Injury, By End User, and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)-Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
价格
简介目录
预估 2023 年全球缺血再灌注伤害治疗药物市场规模为 20.6 亿美元，预测期内（2023-2030 年）复合年增长率为 6%。
| 报告范围 | 报告详细资料 | ||
|---|---|---|---|
| 基准年 | 2022 | 2023 年市场规模 | 20.6亿美元 |
| 过去的资料 | 2018年至2021年 | 预测期间 | 2023-2030 |
| 预测 2023-2030 年复合年增长率： | 6.00% | 2030年价值预测 | 30.9亿美元 |
缺血再灌注损伤（IRI），也称为復氧损伤，是在一段时间缺氧（缺血）后血液供应恢復到组织（再灌注）时发生的组织损伤。缺血性损伤的症状包括心搏过缓、头痛、高血压和抽搐。缺血再灌注伤害伴随心肌冬眠、急性心臟衰竭、脑功能障碍、胃肠功能障碍、全身性发炎反应症候群、多重器官功能障碍症候群等严重临床症状。缺血再灌注伤害是一种严重的医学病症，为医师带来了重要的治疗挑战。
市场动态
主要市场参与者增加治疗再灌注伤害患者的研发活动预计将在预测期内推动市场成长。例如，2022年5月31日，製药公司GNT Pharma报告Nelonemdaz正处于I期临床试验。Neronemdaz (Neu2000) 正在开发用于治疗急性缺血性中风、创伤性脑损伤、创伤性脊髓损伤、急性心肌梗塞 (AMI)、烧伤和脑梗塞。
此外，2021年9月，製药公司GNT Pharma申请的临床试验许可（IND）已获得批准。此次 IND 批准是基于 GNT Pharma 之前的 II 期研究的积极结果。这项 III 期研究的结果对于证明 neronemdaz 作为急性缺血性中风的有效治疗方法的治疗潜力非常重要。
本调查的主要特征
- 本报告提供以2022年为基准年的预测期间（2023-2030 年）之全球缺血再灌流伤害治疗药市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
- 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
- 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
- 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球缺血再灌流伤害治疗药市场的主要参与者之企业简介。
- 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
- 全球缺血再灌流伤害治疗药市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
- 利益相关者可以透过全球缺血再灌流伤害治疗药市场用于分析的各种战略矩阵来帮助他们更容易做下决策。
目录
第1章 调查目的与前提条件
- 调查目的
- 前提条件
- 简称
第2章 市场概况
- 报告概要
- 市场定义和范围
- 摘要整理
- Coherent Opportunity Map(COM)
第3章 市场动态，法规，趋势分析
- 市场动态
- 促进因素
- 阻碍因素
- 市场机会
- 影响分析
- 最近的产品销售
- 流行病学
- 合併，收购，联盟
- 法规情势
- 主要的发展
- PEST分析
- 伙伴关係方案
- 品牌和价格分析
- 分销商的形势
- 波特分析
- 技术的进步
- 主要的发展
- 市场趋势
- 各收益的主要企业
第4章 缺血再灌流伤害治疗药的全球市场:COVID-19影响分析
- 经济影响
- COVID-19流行病学
- 供需的影响
第5章 缺血再灌流伤害治疗药的全球市场:各治疗法，2018年～2030年
- 药物疗法
- 药用天然气(气体)
- 其他(维他命疗法等)
第6章 缺血再灌流伤害治疗药的全球市场:伤害各类型，2018年～2030年
- 心臟损伤
- 肾臟损伤
- 肠损伤
- 其他
第7章 缺血再灌流伤害治疗药的全球市场:各终端用户，2018年～2030年
- 医院
- 专门诊所
- 门诊病人手术中心
- 其他(学术研究机关等)
第8章 缺血再灌流伤害治疗药的全球市场:各地区，2018年～2030年
- 北美
- 美国
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美国家
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 中东
- GCC
- 以色列
- 其他中东
- 非洲
- 北非
- 中非
- 南非
第9章 竞争情形
- Revive Therapeutics Ltd.
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.
第10章 章节
- 调查手法
- 关于出版社
简介目录
Product Code: CMI4105
The global ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 2.06 Bn in 2023 and is expected to exhibit a CAGR of 6% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.06 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 6.00% | 2030 Value Projection: | US$ 3.09 Bn |
Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of an ischemia injury include bradycardia, headache, hypertension, and seizures. Ischemia-reperfusion injury is associated with serious clinical manifestations, including myocardial hibernation, acute heart failure, cerebral dysfunction, gastrointestinal dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. Ischemia-reperfusion injury is a critical medical condition that poses an important therapeutic challenge for physicians.
Market Dynamics
Increasing number of research and development activities by the key market players for the treatment of patients suffering from reperfusion injury is expected to drive the growth of market over the forecast period. For instance, on May 31, 2022, GNT Pharma, a pharmaceutical company,reported that Nelonemdaz is under clinical for phase I clinical trial. Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction.
Furthermore, in September 2021, GNT Pharma, a pharmaceutical company, reported that the Korea Ministry of Food and Drug Safety (MFDS) had approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is based on the encouraging results of GNT Pharma's earlier phase II trials. The outcomes of this phase III study will be instrumental in documenting the therapeutic potential of nelonemdaz as an effective treatment for acute ischemic stroke.
Key features of the study:
- This report provides an in-depth analysis of the global ischemia reperfusion injury therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Revive Therapeutics Ltd., Faraday Pharmaceuticals, Abiomed, Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global medical imaging equipment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ischemia reperfusion injury therapeutics market
Detailed Segmentation:
- Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment:
- Drug Therapy
- Medicated Gas
- Others (Vitamin Therapy and among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type:
- Heart Injury
- Kidney Injury
- Intestine Injury
- Other Injury (Brain Injuries and Among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By End user:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others(Academic and Research Institutes and among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Revive Therapeutics Ltd.
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Injury Type
- Market Snapshot, By End user
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Top Market Players by Revenue
4. Global Ischemia Reperfusion Injury Therapeutics Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Medicated Gas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Others (Vitamin Therapy and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
6. Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Heart Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Intestine Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
7. Global Ischemia Reperfusion Injury Therapeutics Market, By End user, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Others (Academic and Research Institutes and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
8. Global Ischemia Reperfusion Injury Therapeutics Market, By Region, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2018-2030, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018- 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Revive Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.
10. Section
- Research Methodology
- About Us
